Jobs
-
Vertex Pharmaceuticals said that it plans to initiate a Phase 1 SAD trial of its VX-522 inhaled mRNA therapy after the FDA cleared the company’s IND. VX-522 contains lipid nanoparticle-encapsulated mRNA that is designed to… Read more . . .
-
According to Evoke Pharma, the United States Patent and Trademark Office (USPTO) has issued a new patent covering Evoke’s Gimoti metoclopramide nasal spray. The new patent (No. 11,517,545), which expires in 2038, is titled “Treatment… Read more . . .
-
Pulmocide announced that it has closed a $52 million a Series C extension round, with the proceeds to be used for continued development of its PC945 inhaled opelconazole for the treatment of invasive pulmonary Aspergillosis (IPA).… Read more . . .
-
According to Emergent BioSolutions, the FDA has accepted the company’s supplemental NDA for over-the-counter (OTC) sales of Narcan naloxone nasal spray for the reversal of opioid overdose and has set a PDUFA goal date of March… Read more . . .
-
Gossamer Bio has announced that the TORREY Phase 2 study of its GB002 seralutinib DPI for the treatment of pulmonary arterial hypertension (PAH) met its primary endpoint, demonstrating a statistically significant change in pulmonary vascular… Read more . . .
-
The FDA has awarded Fast Track designation to Vistagen’s PH10 pherin nasal spray for the treatment of major depressive disorder, the company said. Vistagen recently announced its plans for a Phase 1 trial of a re-formulated version… Read more . . .
-
TFF Pharmaceuticals, which develops dry powder inhalation products based on its thin film freezing technology, has announced that Glenn Mattes will step down as CEO and that he will be succeeded on an interim basis… Read more . . .
-
The FDA has approved Aucta Pharmaceuticals’ ANDA for its formoterol fumarate inhalation solution, a generic version of Mylan’s Perforomist. Aucta’s is the 4th Perforomist equivalent approved since the expiration of Mylan’s final patent covering the… Read more . . .
-
CDMO Experic, which offers development and manufacturing services for DPIs, announced that it has closed a $14 million series B funding led by East Seattle Partners and inhaler filling experts Harro Höfliger Packaging Systems. The company… Read more . . .
-
Copley Scientific CEO Mark Copley answers questions about the importance of the test environment for OIP testing Why is the test environment so important for inhaler testing? Due to a broad range of factors, including… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland